Adaptam Therapeutics Secures €3m Funding
Adaptam Therapeutics has raised €3m to develop antibody-based cancer immunotherapies targeting myeloid cells.
The pre-seed financing round, led by Criteria Bio Ventures, will enable Adaptam to advance its therapeutic programs into preclinical development across multiple oncology indications.
- Adaptam is pioneering first-in-class antibody therapies, including ADCs and bispecific antibodies.
- These therapies target novel glyco-immune checkpoints expressed in tumor-associated myeloid cells.
- The goal is to overcome the immunosuppressive tumor microenvironment (TME), a significant barrier in cancer treatment.
Adaptam aims to develop innovative cancer therapies.
Dr Salvatore Cappadona and Dr Pablo Cironi from Criteria Bio Ventures have joined Adaptam's board of directors as part of the investment.
Author's summary: Adaptam Therapeutics raises €3m for cancer therapy development.
More News
- Woot Introduces Big Discounts on Samsung's Best Monitors
- D&H Distributing’s Advanced Solutions Plus Unit To Focus On The Enterprise, ‘A Pivotal Evolution’ For Its Business
- Israeli intelligence vets raise $20M to track developer buying signals | TechCrunch
- Canada’s Lululemon Partners With National Football League
- Which Non-League sides will take part in the Isuzu FA Trophy Second Round Proper? - The Non-League Football Paper
- This ‘minor’ bird flu strain has potential to spark human pandemic
- Here’s why Utah’s Olympic organizers are in NYC this week
- OPPO, Ballet Philippines to promote Filipino Artistry with new partnership
- Take $200 Off Every M4 MacBook Air, Available From $799
- Let me explain why I think Star Trek: Enterprise is set in J.J. Abrams' Kelvin Timeline